BR112012012815A2 - composto derivado de 1,3-difenil-prop-2-en-1-ona, uso do referido composto, e composto, e, composição farmacêutica - Google Patents

composto derivado de 1,3-difenil-prop-2-en-1-ona, uso do referido composto, e composto, e, composição farmacêutica

Info

Publication number
BR112012012815A2
BR112012012815A2 BR112012012815A BR112012012815A BR112012012815A2 BR 112012012815 A2 BR112012012815 A2 BR 112012012815A2 BR 112012012815 A BR112012012815 A BR 112012012815A BR 112012012815 A BR112012012815 A BR 112012012815A BR 112012012815 A2 BR112012012815 A2 BR 112012012815A2
Authority
BR
Brazil
Prior art keywords
compound
prop
diphenyl
derivatives
liver
Prior art date
Application number
BR112012012815A
Other languages
English (en)
Other versions
BR112012012815B1 (pt
BR112012012815A8 (pt
BR112012012815B8 (pt
Inventor
Hum Dean
Darteil Raphaël
Hanf Rémy
Original Assignee
Genfit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genfit filed Critical Genfit
Publication of BR112012012815A2 publication Critical patent/BR112012012815A2/pt
Publication of BR112012012815A8 publication Critical patent/BR112012012815A8/pt
Publication of BR112012012815B1 publication Critical patent/BR112012012815B1/pt
Publication of BR112012012815B8 publication Critical patent/BR112012012815B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/782—Ketones containing a keto group bound to a six-membered aromatic ring polycyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

uso de derivados de 1,3-difenilprop-2-en-1-ona para tratar distúrbios hepáticos. a invenção se refere a derivados de 1,3-difenil-prop-2-en-1-ona e a composições farmacêuticas compreendendo trais derivados para tratamento de distúrbios hepáticos, em particular aqueles necessitando da redução do nível plasmático de marcadores bioquímicos, tais como aminotransferases. os derivados de 1,3-difenil-prop-2-en-1-ona de fórmula feral (i) têm propriedades hepatoprotetoras e podem ser usados em métodos para tratar os distúrbios hepáticos envolvendo a perturbação patológica, inflamação, degeneração,e/ou proliferação de células hepáticas, tais como fibrose hepática ou doença do fígado gorduroso.
BR112012012815A 2009-11-26 2010-11-26 uso de um composto selecionado de 1-[4-metil-tio-fenil]-3-[3,5-dimetil-4-carbóxi-dimetil-metilóxi-fenil]prop-2-en-1-ona e ácido 2-[2,6-dimetil-4-[3-[4-(metil-tio)fenil]-3-oxo-propil]fenóxi]-2-metilpropanóico BR112012012815B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09306146 2009-11-26
EP09306146.3 2009-11-26
PCT/EP2010/068346 WO2011064350A1 (en) 2009-11-26 2010-11-26 Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders

Publications (4)

Publication Number Publication Date
BR112012012815A2 true BR112012012815A2 (pt) 2017-12-12
BR112012012815A8 BR112012012815A8 (pt) 2018-02-27
BR112012012815B1 BR112012012815B1 (pt) 2021-02-02
BR112012012815B8 BR112012012815B8 (pt) 2021-05-25

Family

ID=43587223

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012012815A BR112012012815B8 (pt) 2009-11-26 2010-11-26 uso de um composto selecionado de 1-[4-metil-tio-fenil]-3-[3,5-dimetil-4-carbóxi-dimetil-metilóxi-fenil]prop-2-en-1-ona e ácido 2-[2,6-dimetil-4-[3-[4-(metil-tio)fenil]-3-oxo-propil]fenóxi]-2-metilpropanóico

Country Status (24)

Country Link
US (2) US8772342B2 (pt)
EP (2) EP2504005B1 (pt)
JP (4) JP5833016B2 (pt)
KR (2) KR101962209B1 (pt)
CN (2) CN104434891B (pt)
AU (1) AU2010323066B2 (pt)
BR (1) BR112012012815B8 (pt)
CA (1) CA2781451C (pt)
CY (2) CY1116548T1 (pt)
DK (2) DK2641596T3 (pt)
EA (1) EA020849B1 (pt)
ES (2) ES2681794T3 (pt)
HK (1) HK1175716A1 (pt)
HU (1) HUE039731T2 (pt)
IL (2) IL219914A (pt)
LT (1) LT2641596T (pt)
MX (1) MX2012006062A (pt)
NZ (1) NZ600439A (pt)
PL (2) PL2504005T3 (pt)
PT (2) PT2504005E (pt)
SI (2) SI2504005T1 (pt)
TR (1) TR201810393T4 (pt)
WO (1) WO2011064350A1 (pt)
ZA (1) ZA201204658B (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9221751B2 (en) 2009-11-26 2015-12-29 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
KR101962209B1 (ko) 2009-11-26 2019-03-26 장피트 간 질환 치료를 위한 1,3-디페닐프로프-2-엔-1-온 유도체의 용도
US10722575B2 (en) 2009-11-26 2020-07-28 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
WO2012104869A1 (en) 2011-01-31 2012-08-09 Cadila Healthcare Limited Treatment for lipodystrophy
HUE042569T2 (hu) * 2013-01-18 2019-07-29 Genfit Rákok és fibrózis kezelési eljárások
KR101617812B1 (ko) 2013-04-22 2016-05-03 카딜라 핼쓰캐어 리미티드 비알콜성 지방간 질환을 위한 신규 조성물
US20160107989A1 (en) 2013-05-30 2016-04-21 Cadila Healthcare Limited A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities
TW201513857A (zh) 2013-07-05 2015-04-16 Cadila Healthcare Ltd 協同性組成物
IN2013MU02470A (pt) 2013-07-25 2015-06-26 Cadila Healthcare Ltd
US10112898B2 (en) 2013-09-06 2018-10-30 Cadila Healthcare Limited Process for the preparation of saroglitazar pharmaceutical salts
KR102347721B1 (ko) 2014-06-13 2022-01-05 엥방티바 섬유성 질환의 치료에 사용하기 위한 ppar 화합물
DK3253382T3 (da) * 2015-02-06 2022-02-14 Intercept Pharmaceuticals Inc Farmaceutiske sammensætninger til kombinationsterapi
WO2017046181A1 (en) * 2015-09-14 2017-03-23 Genfit Methods for diagnosing and evaluating non-alcoholic steatohepatitis
WO2017064635A2 (en) 2015-10-14 2017-04-20 Cadila Healthcare Limited Pyrrole compound, compositions and process for preparation thereof
US10442761B2 (en) 2016-02-16 2019-10-15 Concert Pharmaceuticals, Inc. Deuterated GFT-505
US11331292B2 (en) 2016-03-31 2022-05-17 Genfit Methods of treatment of cholestatic diseases
US12053445B2 (en) 2016-03-31 2024-08-06 Genfit Methods of treatment of cholestatic diseases
EP4233910A3 (en) * 2016-03-31 2024-01-17 Genfit Methods of treatment of cholestatic diseases
FR3056909B1 (fr) * 2016-09-30 2019-04-19 Nashpharm Composition comprenant au moins un sel pharmaceutiquement acceptable d'elafibranor soluble en milieux aqueux presentant une absorption intestinale amelioree
FR3056908B1 (fr) * 2016-09-30 2019-04-19 Nashpharm Sel de metformine et d'elafibranor presentant une activite duale pour le traitement de l'obesite associee a la steato-hepatite non alcoolique (nash) et a l'hypertriglyceridemie
JP6840853B2 (ja) 2016-12-09 2021-03-10 カディラ・ヘルスケア・リミテッド 原発性胆汁性胆管炎の治療
CN110312705B (zh) * 2017-01-22 2021-07-09 苏州科睿思制药有限公司 Gft-505的晶型及其制备方法和用途
AU2018223976B2 (en) * 2017-02-24 2023-08-17 Genfit Pharmaceutical compositions for combination therapy
US11478440B2 (en) * 2017-04-18 2022-10-25 Genfit Combination of Elafibranor or derivatives thereof with an anti-NASH, anti-fibrotic or anti-cholestatic agent
KR102603436B1 (ko) 2017-11-30 2023-11-16 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 방향족 화합물, 약학적 조성물 및 그 용도
EP3830070A1 (en) 2018-08-03 2021-06-09 Genfit Elafibranor salts
CA3112073A1 (en) * 2018-10-11 2020-04-16 Basf As Aromatic compounds and pharmaceutical uses thereof
RU2702003C1 (ru) * 2019-03-18 2019-10-03 Федеральное государственное бюджетное образовательное учреждение высшего образования "Санкт-Петербургский государственный химико-фармацевтический университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО СПХФУ Минздрава России) Антистеатозное средство
KR20210150436A (ko) * 2019-04-10 2021-12-10 장피트 화학식 (i)의 화합물 및 glp-1 수용체 효현제를 포함하는 병용 요법
CN110143890B (zh) * 2019-06-12 2020-12-22 天津科技大学 一种查尔酮衍生物和合成方法及其在制备抗非酒精性脂肪肝炎药物中的应用
CN110143902B (zh) * 2019-06-12 2021-06-04 天津科技大学 含硒查尔酮衍生物Compound 1和合成方法及在抗非酒精性脂肪肝炎药物中的应用
JP2023513712A (ja) 2020-02-10 2023-04-03 ジェンフィット エラフィブラノールの多形体

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04202129A (ja) 1990-11-30 1992-07-22 Terumo Corp 肝障害治療薬
SK20396A3 (en) * 1993-08-19 1997-03-05 Warner Lambert Co Substituted 2(5h)furanone, 2(5h)thiophenone or 2(5h)pyrrolone derivatives and pharmaceutical compositions on their base
EP1242352A2 (en) 1999-12-23 2002-09-25 University Of Georgia Research Foundation, Inc. Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states
US6608101B1 (en) 2000-06-20 2003-08-19 Atherogenics, Inc. 1, 3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders
KR100567125B1 (ko) 2001-11-01 2006-03-31 주식회사 안지오랩 칼콘 또는 이의 유도체를 함유하는 매트릭스메탈로프로테아제 활성 억제용 약학 조성물
FR2841784B1 (fr) * 2002-07-08 2007-03-02 Composition a base de derives de 1,3-diphenylprop-2en-1-one substitues, preparation et utilisations
FR2841900B1 (fr) 2002-07-08 2007-03-02 Genfit S A Nouveaux derives de 1,3-diphenylprop-2-en-1-one substitues, preparation et utilisations
FR2857361B1 (fr) 2003-07-08 2005-09-09 Genfit S A PREPARATION DE DERIVES DE 1,3-DIPHENYPROP-2-¼n-1-one
KR20060132903A (ko) * 2004-01-08 2006-12-22 장피트 1,3-디페닐프로프-2-엔-1-온 유도체 화합물, 그 제조방법및 용도
JP4689331B2 (ja) 2005-04-19 2011-05-25 三菱電機株式会社 撮像装置
FR2902789A1 (fr) * 2006-06-21 2007-12-28 Genfit Sa Derives de 1,3-diphenylpropane substitues, preparations et utilisations
DE102006062264A1 (de) * 2006-12-22 2008-06-26 Joh. Barth & Sohn Gmbh & Co. Kg Verwendung von Xanthohumol zur Vorbeugung und/oder Bekämpfung von Lebererkrankungen
KR101962209B1 (ko) * 2009-11-26 2019-03-26 장피트 간 질환 치료를 위한 1,3-디페닐프로프-2-엔-1-온 유도체의 용도

Also Published As

Publication number Publication date
WO2011064350A1 (en) 2011-06-03
KR20180031825A (ko) 2018-03-28
PL2641596T3 (pl) 2018-10-31
DK2641596T3 (en) 2018-08-06
EP2504005B1 (en) 2013-11-06
CN102647982A (zh) 2012-08-22
TR201810393T4 (tr) 2018-08-27
CA2781451A1 (en) 2011-06-03
IL241791A0 (en) 2015-11-30
EA201290389A1 (ru) 2013-01-30
HK1175716A1 (en) 2013-07-12
AU2010323066B2 (en) 2014-12-11
US20140309165A1 (en) 2014-10-16
LT2641596T (lt) 2018-08-10
BR112012012815B1 (pt) 2021-02-02
CN102647982B (zh) 2014-10-15
EP2641596A1 (en) 2013-09-25
KR101962209B1 (ko) 2019-03-26
US8772342B2 (en) 2014-07-08
AU2010323066A1 (en) 2012-06-07
US20120252725A1 (en) 2012-10-04
MX2012006062A (es) 2012-06-28
CA2781451C (en) 2019-04-16
JP5833016B2 (ja) 2015-12-16
US8895619B2 (en) 2014-11-25
EA020849B1 (ru) 2015-02-27
KR101865677B1 (ko) 2018-07-16
NZ600439A (en) 2014-06-27
JP2018070642A (ja) 2018-05-10
PT2504005E (pt) 2014-01-10
IL219914A0 (en) 2012-07-31
BR112012012815A8 (pt) 2018-02-27
EP2504005A1 (en) 2012-10-03
CN104434891A (zh) 2015-03-25
KR20120101472A (ko) 2012-09-13
PL2504005T3 (pl) 2014-03-31
SI2504005T1 (sl) 2014-04-30
ES2441665T3 (es) 2014-02-05
BR112012012815B8 (pt) 2021-05-25
DK2504005T3 (da) 2014-01-13
HUE039731T2 (hu) 2019-01-28
CY1116548T1 (el) 2017-03-15
JP6594400B2 (ja) 2019-10-23
JP2013512228A (ja) 2013-04-11
ES2681794T3 (es) 2018-09-17
CY1120444T1 (el) 2019-07-10
EP2641596B1 (en) 2018-05-02
PT2641596T (pt) 2018-07-31
JP2020073468A (ja) 2020-05-14
ZA201204658B (en) 2013-05-29
SI2641596T1 (sl) 2018-09-28
EA201290389A8 (ru) 2014-05-30
JP2016074670A (ja) 2016-05-12
CN104434891B (zh) 2018-03-30
IL219914A (en) 2015-10-29

Similar Documents

Publication Publication Date Title
BR112012012815A2 (pt) composto derivado de 1,3-difenil-prop-2-en-1-ona, uso do referido composto, e composto, e, composição farmacêutica
BR112013028430A2 (pt) composto, composição farmacêutica, método para tratar uma doença ou condição mediada por tirosina quinase do baço (syk), e, uso de uma quantidade terapeuticamente eficiente do composto
EA201490228A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
BRPI0718803B8 (pt) composto para inibir a progressão mitótica, composição farmacêutica e método in vitro para inibir a atividade de aurora cinase em uma célula
CR10211A (es) Compuestos de tiazol y métodos de uso
BRPI0622054B8 (pt) composto e composição farmacêutica
EP2381775A4 (en) INHIBITORS OF NECROPTOSIS OF SMALL MOLECULAR SIZE
ATE495743T1 (de) Triazolopyridinverbindungen zur behandlung von degenerations- und entzündungskrankheiten
NO20092444L (no) Heteroarylamidderivater
CR10458A (es) Compuestos de triazolopirazina utiles para el tratamiento de enfermedades degenerativas e inflamatorias
ECSP078013A (es) Inhibidores heterocíclicos de mek y métodos de uso de ellos
NO20090434L (no) Heteroarylforbindelser anvendbare som inhibitorer av E1-aktiverende enzymer
BRPI0913580B8 (pt) compostos de pirrolopiridinas como inibidores de quinase e composição farmacêutica compreendendo os referidos compostos
BR112014030812A2 (pt) "compostos tricíclicos substituídos como inibidores de fgfr, seus usos, composição farmacêutica e método para inibir uma enzima fgfr"
DK2321321T3 (da) Triazolo [4,5-d]pyramidinderivater og anvendelse deraf som purinreceptorantagonister
BRPI0818533B8 (pt) composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
EA201491060A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
NI200800253A (es) Tetrahidro-pirimidoazepinas como moduladores de trpv1
EP2321264A4 (en) DEACETYLASEINHIBITORS AND APPLICATIONS THEREOF
CR10566A (es) Compuestos heterociclicos adecuados para el tratamiento de enfermedades relacionadas con nivel elevado de lipidos
EA201170832A1 (ru) Пуриновые соединения
PH12013502370A1 (en) Multiheteroaryl compounds as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
BRPI0806863B8 (pt) uso de um éster de forbol na preparação de um medicamento para prevenção ou tratamento de uma infecção por hiv
BRPI0914305B8 (pt) compostos de piridazina carboxamida substituída como compostos inibidores da quinase, uso dos compostos e uso de uma composição compreendendo os compostos
BR112013001632A2 (pt) composto, composição farmacêutica, método de inibir uma atividade uma jak quinase in vitro, uso de um composto, ou da composição farmacêutica, e, método de fabricar um composto

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09Y Publication of grant cancelled [chapter 9.1.2 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 9.1 NA RPI NO 2603 DE 24/11/2020 POR TER SIDO INDEVIDA. O PARECER EMQUESTAO POSSUI INCORRECOES POIS NO QUADRO 1 DEIXOU DE MENCIONAR A VIA RELATIVA A SEQUENCIAGENETICA.

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/02/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/11/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF